– First subject treated in SYNB1891 immuno-oncology study, data from monotherapy arm expected in 2020 – – Expansion of pipeline with new preclinical programs in secondary hyperoxaluria and maple syrup urine disease (MSUD) – – Phase 2 clinical trial of solid...
NEW YORK, Jan. 08, 2020 (GLOBE NEWSWIRE) — Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that the first pancreatic cancer patient has been dosed in Part 2 of the...
Sites now have access to a free eRegulatory application to simplify regulatory compliance and speed study execution PLEASANTON, Calif.–(BUSINESS WIRE)–Veeva Systems (NYSE:VEEV) today announced the availability of Veeva SiteVault Free, a free eRegulatory...
– IOVaxis buys an exclusive option to license the TG01/02 cancer vaccines for China, Hong Kong, Macau and Singapore, for a fee of USD 250.000 – If exercised, the license has a potential value of up to USD 100 million in development and commercial...
– Duchenne UK Grants Over $600,000 in Funding to Support Patient and Clinical Trial Site Costs — BOSTON–(BUSINESS WIRE)–Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, and Duchenne UK, a charity that...
Texas Medical Center is the largest medical complex in the world with 10 million patient encounters per year and a 1,345-acre campus (50 million square feet of developed facilities) InFoods® Diagnostic Guided Therapy (DGT) is designed to identify patient specific...
Email
Text